Brief: Simcere Pharmaceutical Says Clinical Trial Approval For New Indication Of Sanbexin Sublingual Tablets
30/11/2023 12:39
Nov 30 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* CLINICAL TRIAL APPROVAL FOR NEW INDICATION OF SANBEXIN
SUBLINGUAL TABLETS ISSUED BY PRC'S NMPA
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660